Investing.com - Kiniksa Pharma (NASDAQ: KNSA) reported third quarter EPS of $-0.20, $0.03 worse than the analyst estimate of $-0.17. Revenue for the quarter came in at $67.05M versus the consensus estimate of $64.55M.
Kiniksa Pharma's stock price closed at $15.68. It is down -14.32% in the last 3 months and up 22.50% in the last 12 months.
Kiniksa Pharma saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Kiniksa Pharma's stock price’s past reactions to earnings here.
According to InvestingPro, Kiniksa Pharma's Financial Health score is "great performance".
Check out Kiniksa Pharma's recent earnings performance, and Kiniksa Pharma's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar